Efficacy of venetoclax as targeted therapy for relapsed/refractory t(11;14) multiple myeloma-Reference-Cited by-同舟云学术

Efficacy of venetoclax as targeted therapy for relapsed/refractory t(11;14) multiple myeloma

Published:2017-11-30 Issue:22 Volume:130 Page:2401-2409
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Kumar Shaji¹^ORCID,Kaufman Jonathan L.²,Gasparetto Cristina³,Mikhael Joseph⁴,Vij Ravi⁵,Pegourie Brigitte⁶,Benboubker Lofti⁷,Facon Thierry⁸,Amiot Martine⁹,Moreau Philippe⁹,Punnoose Elizabeth A.¹⁰,Alzate Stefanie¹¹,Dunbar Martin¹¹,Xu Tu¹¹,Agarwal Suresh K.¹¹,Enschede Sari Heitner¹¹,Leverson Joel D.¹¹,Ross Jeremy A.¹¹,Maciag Paulo C.¹¹,Verdugo Maria¹¹,Touzeau Cyrille⁹

Affiliation:

1. Mayo Clinic, Rochester, MN;

2. Winship Cancer Institute of Emory University, Atlanta, GA;

3. Hematologic Malignancies & Cellular Therapy, Duke University, Durham, NC;

4. Mayo Clinic, Scottsdale, AZ;

5. Washington University School of Medicine, St. Louis, MO;

6. Centre Hospitalier Universitaire, Grenoble, France;

7. Centre Hospitalier Regional Universitaire, Tours, France;

8. Centre Hospitalier Regional Universitaire Lille, Hopital Huriez, Lille, France;

9. Centre Hospitalier Universitaire de Nantes, INSERM, Université de Nantes, France;

10. Genentech Inc., South San Francisco, CA; and

11. AbbVie Inc., North Chicago, IL

Abstract

Key Points Venetoclax monotherapy at a daily dose up to 1200 mg has an acceptable safety profile in patients with relapsed/refractory MM. Venetoclax monotherapy has demonstrated antimyeloma activity in patients with relapsed/refractory MM positive for t(11;14).

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/130/22/2401/1403484/blood788786.pdf

Reference32 articles.

1. Novel agents in the treatment of multiple myeloma: a review about the future;Naymagon;J Hematol Oncol,2016

2. Reprogramming cell death: BCL2 family inhibition in hematological malignancies;Scarfò;Immunol Lett,2013

3. Thirty years of BCL-2: translating cell death discoveries into novel cancer therapies;Delbridge;Nat Rev Cancer,2016

4. Apoptosis therapy: driving cancers down the road to ruin;Green;Nat Med,2013

5. ABT-737 is highly effective against molecular subgroups of multiple myeloma;Bodet;Blood,2011

Cited by 409 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Precision medicine for multiple myeloma: The case for translocation (11;14);Cancer Treatment Reviews;2024-11

2. Design, synthesis, and biological activity evaluation of novel HDAC3 selective inhibitors for combination with Venetoclax against acute myeloid leukemia;European Journal of Medicinal Chemistry;2024-10

3. Flow cytometric expression of Bcl-2, Mcl-1, and their ratios correlates with primary and secondary cytogenetic changes and their combinations in multiple myeloma;Annals of Hematology;2024-09-12

4. Biomarker-directed therapy in multiple myeloma;Current Opinion in Oncology;2024-08-23

5. Updates on Therapeutic Strategies in the Treatment of Relapsed/Refractory Multiple Myeloma;Cancers;2024-08-23